CARD6

Across TCGA pan-cancer cohorts, CARD6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CARD6 data layer compared with 23 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher CARD6 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CARD6 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where CARD6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.975	0.214	.001	13	view →
LSCC	DFS	Tertile	All	0.535	0.836	.003	10	view →
HNSC	DFS	Median	III,IV	0.523	0.745	.031	5	view →
CCRCC	DFS	Quartile	II,III,IV	0.074	0.904	.038	4	view →
LUAD	OS	Median	II,III,IV	0.417	0.783	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CARD6–PDAC (DFS)

Open the PDAC breakdown →